2-Aryl Propionic Acid Amide Modification of Naproxen and Ibuprofen Dimers for Anti-neuroinflammatory Activity in BV2 mouse Microglial Cells

다국어 초록 (Multilingual Abstract)

Inflammation is a common link in the pathophysiology of many neurological illnesses, including Alzheimer’s disease. Activated glial cells contribute to neuroinflammation by producing pro-inflammatory mediators. Naproxen and ibuprofen are nonsteroidal anti-inflammatory drugs with 2-aryl(s) propionic acid as a common pharmacophore. Here we designed a small series of naproxen and ibuprofen amide dimers and tested their effects on the expression of inducible nitric oxide synthase (iNOS), a neuroinflammatory enzyme in lipopolysaccharide (LPS)-stimulated BV2 mouse microglial cells. Of note, treatment with CNU 019, 020, 021, 023, 024, and 027 at 10 M markedly inhibited the LPS-induced iNOS expression in BV2 cells. CNU 024 was tested further at different concentrations to regulate the LPS-induced iNOS expression in BV2 cells. Treatment with CNU 024 at 5, 10, or 20 M dose-dependently suppressed the LPS-induced iNOS protein and mRNA expression levels in BV2 cells, in which maximal inhibition was seen at 20 M. CNU 024 treatment at doses tested further led to a concentration-dependent inhibition of the LPS-induced phosphorylation (activation) of p38 mitogen-activated protein kinase (MAPK) without influencing its total protein expression in BV2 cells, but it did not affect the LPS-induced activation of c-jun N-terminal kinase-1/2 and extracellular signal-regulated kinases-1/2 in these cells. In summary, our results demonstrate that CNU 024 inhibits the LPS-induced iNOS expression in BV2 cells, partly mediated by the inhibition of p38 MAPK. This work shows that CNU 024 could be a valuable ligand for further development as a potential drug candidate for treating neuroinflammatory pathologies.

참고문헌 (Reference)

1 Christian F, "The regulation of NF-κB subunits by phosphorylation" 5 : 2016

2 Justo AFO, "The modulation of neuroinflammation by inducible nitric oxide synthase" 16 : 155-158, 2022

3 Sonar SA, "The iNOS activity during an immune response controls the CNS pathology in experimental autoimmune encephalomyelitis" 10 : 710-, 2019

4 Oeckinghaus A, "The NF-kappaB family of transcription factors and its regulation" 1 : a000034-, 2009

5 Qu W, "Targeting iNOS alleviates early brain injury after experimental subarachnoid hemorrhage via promoting ferroptosis of M1 microglia and reducing neuroinflammation" 59 : 3124-3139, 2022

6 Cairns H, "Synthesis and structure-activity relationships of disodium cromoglycate and some related compounds" 15 : 583-589, 1972

7 Wang WY, "Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease" 3 : 136-, 2015

8 Ricciotti E, "Prostaglandins and inflammation" 31 : 986-1000, 2011

9 Halen PK, "Prodrug designing of NSAIDs" 9 : 124-139, 2009

10 Kim AR, "Phlorofucofuroeckol A suppresses expression of inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines via inhibition of nuclear factor-κB, c-Jun NH2-terminal kinases, and Akt in microglial cells" 36 : 259-271, 2013

11 Aboul-Fadl T, "Pharmacokinetic studies of naproxen amides of some amino acid esters with promising colorectal cancer chemopreventive activity" 76 : 370-379, 2018

12 Gasparini L, "Non-steroidal anti-inflammatory drugs(NSAIDs)in Alzheimer’s disease : old and new mechanisms of action" 91 : 521-536, 2004

13 Klegeris A, "Non-steroidal anti-inflammatory drugs(NSAIDs)and other anti-inflammatory agents in the treatment of neurodegenerative disease" 2 : 355-365, 2005

14 Ajmone-Cat MA, "Non-steroidal anti-inflammatory drugs and brain inflammation : effects on microglial functions" 3 : 1949-1965, 2010

15 Liy PM, "Nitric oxide modulation in neuroinflammation and the role of mesenchymal stem cells" 246 : 2399-2406, 2021

16 Melih D, "Nitric Oxide Synthase" IntechOpen 2017

17 Aid S, "Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2" 5 : 17-, 2008

18 Krause DL, "Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer’s disease" 2010 : 2010

19 Leng F, "Neuroinflammation and microglial activation in Alzheimer disease : where do we go from here?" 17 : 157-172, 2021

20 Kempuraj D, "Neuroinflammation Induces Neurodegeneration" 1 : 2016

21 Ozben T, "Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease" 72 : 87-89, 2019

22 Kim S, "Naproxen interferes with the assembly of Aβ oligomers implicated in Alzheimer’s disease" 100 : 2024-2032, 2011

23 Azam F, "NSAIDs as potential treatment option for preventing amyloid β toxicity in Alzheimer’s disease : an investigation by docking, molecular dynamics, and DFT studies" 36 : 2099-2117, 2018

24 Ju Hwang C, "NF-κB as a key mediator of brain inflammation in Alzheimer’s disease" 18 : 3-10, 2019

25 Lleo A, "Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases" 64 : 1403-1418, 2007

26 Jang Y, "Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception" 17 : 30-, 2020

27 Bae JH, "Manganese induces inducible nitric oxide synthase(iNOS)expression via activation of both MAP kinase and PI3K/Akt pathways in BV2 microglial cells" 398 : 151-154, 2006

28 Choi Y, "Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells" 156 : 933-940, 2009

29 Esshili A, "Induction of inducible nitric oxide synthase expression in activated microglia and astrocytes following pre-and postnatal immune challenge in an animal model of schizophrenia" 35 : 100-110, 2020

30 Sierra A, "Expression of inducible nitric oxide synthase(iNOS)in microglia of the developing quail retina" 9 : e106048-, 2014

31 Zhang C, "Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis" 8 : 1144-, 2018

32 Jang BC, "Catalase induced expression of inflammatory mediators via activation of NF-kappaB, PI3K/AKT, p70S6K, and JNKs in BV2microglia" 17 : 625-633, 2005

33 Thomas T, "Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation" 12 : 3263-3267, 2001

34 Husain A, "Amide derivatives of sulfonamides and isoniazid : synthesis and biological evaluation" 66 : 513-521, 2009

35 Estes ML, "Alterations in immune cells and mediators in the brain: it’s not always neuroinflammation!" 24 : 623-630, 2014

36 Bhatia HS, "Alleviation of microglial activation induced by p38 MAPK/MK2/PGE(2)axis by capsaicin : potential involvement of other than TRPV1 mechanism/s" 7 : 116-, 2017

37 Cai Y, "Activated microglia are less vulnerable to hemin toxicity due to nitric oxide-dependent inhibition of JNK and p38 MAPK activation" 187 : 1314-1321, 2011

38 Benek O, "A perspective on multi-target drugs for Alzheimer’s disease" 41 : 434-445, 2020

39 Hori Y, "A food and drug administration-approved asthma therapeutic agent impacts amyloid β in the brain in a transgenic model of Alzheimer disease" 290 : 1966-1978, 2015

40 전완주 ; 이희제 ; 김성수 ; 권용수, "3,4,5-Trihydroxycinnamic Acid Inhibits LPS-Induced iNOS Expression by Suppressing NF-κB Activation in BV2 Microglial Cells" 대한약리학회 16 (16): 107-112, 2012